UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 660

Sortiert nach

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

Annals of oncology, 2003-09, Vol.14 (9), p.1430-1437

2003

Volltextzugriff (PDF)

Phase II Study of Liposomal Cisplatin (SPI-77) in Platinum-sensitive Recurrences of Ovarian Cancer

Anticancer research, 2010-02, Vol.30 (2), p.541-545

2010

Volltextzugriff (PDF)

Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development

Annals of oncology, 2009-04, Vol.20 (4), p.609-614

2009

Volltextzugriff (PDF)

Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2000-01, Vol.18 (1), p.106-115

2000

Volltextzugriff (PDF)

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation

Journal of clinical oncology, 1997-03, Vol.15 (3), p.987-993

1997

Volltextzugriff (PDF)

Camptothecins: a review of their development and schedules of administration

European journal of cancer (1990), 1998-09, Vol.34 (10), p.1500-1508

1998

Volltextzugriff (PDF)

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

Annals of oncology, 2012-12, Vol.23 (12), p.3104-3110

2012

Volltextzugriff (PDF)

BRCA-deficient animal models and cisplatin resistance

Annals of oncology, 2009-05, Vol.20 (5), p.962-962

Muggia, F.

2009

Volltextzugriff (PDF)

Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention

Clinical cancer research, 1999-01, Vol.5 (1), p.7-8

Muggia, F M

1999

Volltextzugriff (PDF)

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups

Annals of oncology, 2013-11, Vol.24 Suppl 8, p.viii63-viii68

2013

Volltextzugriff (PDF)

Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study

JNCI : Journal of the National Cancer Institute, 1998-02, Vol.90 (4), p.300-306

1998

Volltextzugriff (PDF)

Development of Tumor-infiltrating Lymphocytes in Breast Cancer after Neoadjuvant Paclitaxel Chemotherapy

Clinical cancer research, 2001-10, Vol.7 (10), p.3025-3030

2001

Volltextzugriff (PDF)

BRCA genes: lessons learned from experimental and clinical cancer

Annals of oncology, 2011, Vol.22, p.i7-i10

2011

Volltextzugriff (PDF)

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6107-6116

2005

Volltextzugriff (PDF)

Hereditary breast and ovarian cancer: lessening the burden

Annals of oncology, 2013-11, Vol.24 Suppl 8, p.viii5-viii6

2013

Volltextzugriff (PDF)

A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity

Cancer chemotherapy and pharmacology, 2013-11, Vol.72 (5), p.1073-1078

2013

Volltextzugriff (PDF)

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

Journal of clinical oncology, 1995-06, Vol.13 (6), p.1303-1311

1995

Volltextzugriff (PDF)

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

Gynecologic oncology, 2007-03, Vol.104 (3), p.727-731

2007

Volltextzugriff (PDF)

Hereditary breast and ovarian cancer: risks and challenges. 10-12 September 2009: Bari, Italy. Introduction

Annals of oncology, 2011-01, Vol.22 Suppl 1, p.i5-i6

2011

Volltextzugriff (PDF)

Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer

Annals of oncology, 2007-04, Vol.18 (4), p.716-721

2007

Volltextzugriff (PDF)

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies

Journal of clinical oncology, 1995-07, Vol.13 (7), p.1777-1785

1995

Volltextzugriff (PDF)

Phase III data on Caelyx® in ovarian cancer

European journal of cancer (1990), 2001-12, Vol.37, p.15-18

2001

Volltextzugriff (PDF)

Conclusions: fruits of the convergence of laboratory, clinic and public

Annals of oncology, 2011, Vol.22, p.i67-i68

2011

Volltextzugriff (PDF)

An evaluation of molecular markers that predict maximal surgical cytoreduction: A Gynecologic Oncology Group trial

Gynecologic oncology, 2013-07, Vol.130 (1), p.e20-e20

2013

Volltextzugriff (PDF)

Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers

Drugs (New York, N.Y.), 1997, Vol.54 Suppl 4, p.22

Muggia, F M

1997

Volltextzugriff (PDF)

1 – 25 von 660

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(559)
Mit Volltextzugriff
(442)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(492)
Science & Technology
(399)
Life Sciences & Biomedicine
(398)
Oncology
(313)
Female
(257)
Middle Aged
(199)
Adult
(169)
Biological And Medical Sciences
(168)
Medical Sciences
(168)
Male
(166)
Aged
(163)
Pharmacology. Drug Treatments
(131)
Antineoplastic Agents
(115)
Chemotherapy
(96)
Neoplasms - Drug Therapy
(95)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(86)
Antineoplastic Agents - Therapeutic Use
(67)
Drug Evaluation
(65)
Animals
(63)
Ovarian Neoplasms - Drug Therapy
(61)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

Phase II Study of Liposomal Cisplatin (SPI-77) in Platinum-sensitive Recurrences of Ovarian Cancer

Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development

Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation

Camptothecins: a review of their development and schedules of administration

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

BRCA-deficient animal models and cisplatin resistance

Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups

Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study

Development of Tumor-infiltrating Lymphocytes in Breast Cancer after Neoadjuvant Paclitaxel Chemotherapy

BRCA genes: lessons learned from experimental and clinical cancer

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

Hereditary breast and ovarian cancer: lessening the burden

A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

Hereditary breast and ovarian cancer: risks and challenges. 10-12 September 2009: Bari, Italy. Introduction

Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies

Phase III data on Caelyx® in ovarian cancer

Conclusions: fruits of the convergence of laboratory, clinic and public

An evaluation of molecular markers that predict maximal surgical cytoreduction: A Gynecologic Oncology Group trial

Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers

Suchergebnisse filtern